Intracellular Company Top Insiders
ITCI Stock | USD 131.60 0.07 0.05% |
Intracellular's insiders are aggressively selling. The analysis of insiders' sentiment of trading Intracellular Th stock suggests that almost all insiders are panicking at this time. Intracellular employs about 860 people. The company is managed by 15 executives with a total tenure of roughly 52 years, averaging almost 3.0 years of service per executive, having 57.33 employees per reported executive.
Sharon Mates Chairman Co-Founder, Chairman, CEO and Pres |
Robert Davis President Senior Vice President and Chief Scientific Officer |
Insider Sentiment 0
Mostly Selling
Selling | Buying |
Latest Trades
2025-01-24 | Josh Gottheimer | Disposed @ 127.35 | |||
2024-12-04 | Sharon Mates | Disposed 51000 @ 85.8 | View | ||
2024-11-12 | Michael Halstead | Disposed 22869 @ 89.12 | View | ||
2024-08-30 | Sharon Mates | Disposed 34396 @ 72.84 | View | ||
2024-08-27 | Sharon Mates | Disposed 40513 @ 73.58 | View | ||
2024-08-23 | Sharon Mates | Disposed 28680 @ 74.46 | View | ||
2024-08-21 | Sharon Mates | Disposed 53013 @ 75.65 | View | ||
2024-08-16 | Mark Neumann | Disposed 18714 @ 75.08 | View | ||
2024-06-24 | Rory B Riggs | Disposed 4462 @ 75.57 | View | ||
2024-06-21 | Josh Gottheimer | Disposed @ 76.58 | |||
2024-06-18 | Nostrand Robert L Van | Disposed 20000 @ 75.91 | View |
Monitoring Intracellular's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Intracellular |
Intracellular's Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Intracellular's future performance. Based on our forecasts, it is anticipated that Intracellular will maintain a workforce of under 860 employees by April 2025.Intracellular's latest congressional trading
Congressional trading in companies like Intracellular Th, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in Intracellular by those in governmental positions are based on the same information available to the general public.
2025-02-11 | Representative Josh Gottheimer | Acquired Under $15K | Verify |
Intracellular Management Team Effectiveness
The company has return on total asset (ROA) of (0.0696) % which means that it has lost $0.0696 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.0858) %, meaning that it created substantial loss on money invested by shareholders. Intracellular's management efficiency ratios could be used to measure how well Intracellular manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -0.06. The current Return On Capital Employed is estimated to decrease to -0.11. As of now, Intracellular's Non Current Assets Total are increasing as compared to previous years. The Intracellular's current Non Currrent Assets Other is estimated to increase to about 46.9 M, while Other Assets are projected to decrease to under 94 K.The current Common Stock Shares Outstanding is estimated to decrease to about 59.3 M. The Intracellular's current Net Loss is estimated to increase to about (219.1 M)
Intracellular Workforce Comparison
Intracellular Th is rated below average in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 17,874. Intracellular holds roughly 860 in number of employees claiming about 5% of equities under Health Care industry.
The company has Profit Margin (PM) of (0.11) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.15) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.15. Intracellular Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Intracellular insiders, such as employees or executives, is commonly permitted as long as it does not rely on Intracellular's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Intracellular insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
---|---|---|---|---|---|
2025-03-01 | 0.7586 | 22 | 29 | 495,052 | 313,281 |
2024-12-01 | 0.3846 | 5 | 13 | 144,495 | 288,560 |
2024-09-01 | 0.4615 | 12 | 26 | 358,255 | 611,424 |
2024-06-01 | 1.6364 | 18 | 11 | 95,725 | 90,750 |
2024-03-01 | 0.39 | 39 | 100 | 887,304 | 1,202,436 |
2023-12-01 | 0.625 | 5 | 8 | 77,081 | 190,409 |
2023-09-01 | 0.5 | 3 | 6 | 55,750 | 212,442 |
2023-06-01 | 1.6667 | 15 | 9 | 126,522 | 183,708 |
2023-03-01 | 0.4688 | 30 | 64 | 673,667 | 562,667 |
2022-12-01 | 0.4286 | 3 | 7 | 50,418 | 148,083 |
2022-09-01 | 0.5556 | 5 | 9 | 95,639 | 210,328 |
2022-06-01 | 2.0 | 12 | 6 | 240,801 | 269,044 |
2022-03-01 | 0.403 | 27 | 67 | 468,105 | 761,391 |
2021-12-01 | 0.3846 | 10 | 26 | 366,834 | 781,697 |
2021-09-01 | 4.0 | 4 | 1 | 11,039 | 10,000 |
2021-06-01 | 1.2222 | 11 | 9 | 168,459 | 165,823 |
2021-03-01 | 0.6512 | 28 | 43 | 560,919 | 519,274 |
2020-12-01 | 0.6667 | 12 | 18 | 212,510 | 483,583 |
2020-09-01 | 2.3333 | 7 | 3 | 99,569 | 88,966 |
2020-06-01 | 1.7143 | 12 | 7 | 142,629 | 110,909 |
2020-03-01 | 0.75 | 30 | 40 | 698,471 | 511,991 |
2019-12-01 | 1.6667 | 10 | 6 | 63,554 | 50,854 |
2019-06-01 | 3.4 | 17 | 5 | 430,130 | 468,378 |
2019-03-01 | 0.9189 | 34 | 37 | 1,315,785 | 316,920 |
2018-12-01 | 2.3333 | 14 | 6 | 215,903 | 97,157 |
2018-03-01 | 1.0952 | 23 | 21 | 739,857 | 146,936 |
2017-12-01 | 2.8333 | 17 | 6 | 1,004,294 | 59,407 |
2017-03-01 | 2.0 | 26 | 13 | 615,307 | 167,770 |
2016-12-01 | 3.0 | 18 | 6 | 321,663 | 19,882 |
2016-03-01 | 20.0 | 20 | 1 | 552,133 | 10,000 |
2015-12-01 | 0.6765 | 23 | 34 | 264,600 | 521,021 |
2015-09-01 | 2.0 | 6 | 3 | 13,640 | 22,700 |
2015-06-01 | 3.5 | 14 | 4 | 148,929 | 60,000 |
2015-03-01 | 4.25 | 17 | 4 | 1,447,315 | 32,500 |
2014-12-01 | 3.0 | 33 | 11 | 269,684 | 174,700 |
2014-09-01 | 2.0 | 8 | 4 | 140,997 | 43,100 |
2014-06-01 | 3.6 | 18 | 5 | 667,702 | 64,242 |
2014-03-01 | 5.0 | 5 | 1 | 97,142 | 0.00 |
2013-12-01 | 1.0 | 1 | 1 | 12,500 | 12,500 |
Intracellular Notable Stakeholders
An Intracellular stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Intracellular often face trade-offs trying to please all of them. Intracellular's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Intracellular's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Sharon Mates | Co-Founder, Chairman, CEO and Pres | Profile | |
Robert Davis | Senior Vice President and Chief Scientific Officer | Profile | |
Mark Neumann | Executive Vice President Chief Commercial Officer | Profile | |
Juan Sanchez | Vice President - Corporate Communications and Investor Relations | Profile | |
John Bardi | Senior Vice President - Market Access, Policy and Government Affairs | Profile | |
John Condon | General President | Profile | |
Michael Olchaskey | Senior Vice President Head of Regulatory Affairs | Profile | |
Sanjeev Narula | Executive CFO | Profile | |
Lawrence CPA | CFO, Finance | Profile | |
Michael JD | General VP | Profile | |
CPA CPA | CFO, Fin | Profile | |
Juan MD | Vice Relations | Profile | |
Suresh MD | Executive Officer | Profile | |
Karen Esq | Senior Officer | Profile | |
Willie MD | Senior Development | Profile |
About Intracellular Management Performance
The success or failure of an entity such as Intracellular Th often depends on how effective the management is. Intracellular management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Intracellular management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Intracellular management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.05) | (0.06) | |
Return On Capital Employed | (0.10) | (0.11) | |
Return On Assets | (0.05) | (0.06) | |
Return On Equity | (0.07) | (0.07) |
Intracellular Workforce Analysis
Traditionally, organizations such as Intracellular use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Intracellular within its industry.Intracellular Manpower Efficiency
Return on Intracellular Manpower
Revenue Per Employee | 791.7K | |
Revenue Per Executive | 45.4M | |
Net Loss Per Employee | 86.8K | |
Net Loss Per Executive | 5M | |
Working Capital Per Employee | 1.3M | |
Working Capital Per Executive | 73.4M |
Complementary Tools for Intracellular Stock analysis
When running Intracellular's price analysis, check to measure Intracellular's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Intracellular is operating at the current time. Most of Intracellular's value examination focuses on studying past and present price action to predict the probability of Intracellular's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Intracellular's price. Additionally, you may evaluate how the addition of Intracellular to your portfolios can decrease your overall portfolio volatility.
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format |